Clinical trial
Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced Stage, Non-small Cell Lung Cancer Patients Receiving 1st Line Doublet Chemotherapy and 2nd Line Target Therapy
NCT01802021 is registered in ClinicalTrials.gov with Chang Gung Memorial Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced Stage, Non-small Cell Lung Cancer Patients Receiving 1st Line Doublet Chemotherapy and 2nd Line Target Therapy
- Lead sponsor
- Chang Gung Memorial Hospital
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- May 31, 2009
- Completion date
- February 28, 2014
- Enrollment
- 120 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.